Matthew Burke on the Prevalence of Immunotherapy AEs

Article

Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale-New Haven Hospital, discusses the prevalence of immunotherapy-related adverse events.

Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale-New Haven Hospital, discusses the prevalence of immunotherapy-related adverse events.

Burke says that approximately one-third of patients will develop a clinically-significant adverse drug reaction. Occasionally, these can develop into moderate or severe side effects. The three side effects that concern Burke most are dermatitis, enterocolitis, and endocrinopathy.

The prevalence of immunotherapy-related side effects is consistent across all studies, versions, and combinations of drugs, Burke says.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Related Content